Clinical hurdles and possible solutions in the implementation of closed-loop control in type 1 diabetes mellitus

Journal of Diabetes Science and Technology

Volumn 5, Issue 5, 2011, Pages 1283-1286

  Zisser, Howard ^a  

^a SANSUM DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

Artificial pancreas; Continuous glucose monitors; Glucagon; Inhaled insulin; Intraperitoneal insulin; Pramlintide; Type 1 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ALGORITHM; ARTICLE; ARTIFICIAL PANCREAS; BLOOD; EQUIPMENT DESIGN; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS;

ALGORITHMS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PANCREAS, ARTIFICIAL;

EID: 84857375491     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500537     Document Type: Note

References (19)

1. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W, Schipper H, Gander R. Clinical control of diabetes by the artificial pancreas. Diabetes. 1974;23(5):397-404.
2. Clemens AH, Chang PH, Myers RW. The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). Horm Metab Res. 1977;Suppl 7:23-33.
3. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med. 2006;23(1):1-12.
4. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934-9.
5. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4(5):673-82.
6. Kumareswaran K, Harris J, Elleri D, Allen JM, Nodale M, Weston J, Wilinska ME, Dunger DB, Amiel SA, Heller SR, Evans ML, Hovorka R. Overnight closed loop (CL) glucose control following consumption of alcohol in adults with type 1 diabetes (T1D). ADA. 2010;Abstract 0358-OR.
7. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G. Amylin: history and overview. Diabet Med. 1997;14 Suppl 2:S9-13.
8. Liebl A, Hoogma R, Renard E, Geelhoed-Duijvestijn PH, Klein E, Diglas J, Kessler L, Melki V, Diem P, Brun JM, Schaepelynck-Bélicar P, Frei T; European DiaPort Study Group. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes Metab. 2009;11(11):1001-8.
9. Botz CK, Leibel BS, Zingg W, Gander RE, Albisser AM. Comparison of peripheral and portal routes of insulin infusion by a computer-controlled insulin infusion system (artificial endocrine pancreas). Diabetes. 1976;25(8):691-700.
10. Keller U, Schade DS. Current status of portable insulin infusion devices. Satellite workshop on portable insulin infusion devices. (Preceding the XVth annual meeting of the European Society for Clinical Investigation) 18-19 March 1981, Basel, Switzerland. Diabetologia. 1981;21(4):425-6.
11. Giacca A, Caumo A, Galimberti G, Petrella G, Librenti MC, Scavini M, Pozza G, Micossi P. Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects. J Clin Endocrinol Metab. 1993;77(3):738-42.
12. Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. Diabetes Care. 2010;33(1):121-7.
13. Rave K, Potocka E, Heinemann L, Heise T, Boss AH, Marino M, Costello D, Chen R. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11(7):715-20.
14. Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther. 2009;11(6):345-52.
15. Finan DA, Zisser H, Jovanovič L, Bevier WC, Seborg DE. Automatic detection of stress states in type 1 diabetes subjects in ambulatory conditions. Ind Eng Chem Res. 2010;49(17):7843-8.
16. Dassau E, Jovanovic L, Doyle FJ 3rd, Zisser HC. Enhanced 911/global position system wizard: a telemedicine application for the prevention of severe hypoglycemia - monitor, alert, and locate. J Diabetes Sci Technol. 2009;3(6):1501-6.
17. Peyser T, Zisser H, Khan U, Jovanovič L, Bevier W, Romey M, Suri J, Strasma P, Tiaden S, Gamsey S. Use of a novel fluorescent glucose sensor in volunteer subjects with type 1 diabetes mellitus. J Diabetes Sci Technol. 2011 May 1;5(3):687-93.
18. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J. 1922;12(3):141-6.
19. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther. 2009;11 Suppl 1:S113-9.